Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant

Conditions:   Hematologic Diseases;   Chronic Myeloid Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Myelodysplastic Syndromes;   Non Hodgkin Lymphoma;   Stem Cell Transplant Complications;   Chronic Lymphocytic Leukemia Intervention:   Other: No intervention Sponsor:   Rigshospitalet, Denmark Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

ConclusionChemotherapy followed by ASCT using a conditioning regimen of reduced melphalan and pharmacokinetically targeted busulfan is a promising strategy for treating patients with relapsed or refractory DLBCL who also have end-stage renal disease and are receiving hemodialysis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
UCLA scientists have discovered a link between a protein and the ability of human blood stem cells to self-renew. In astudy published today in the journal Nature, the team reports that activating the protein causes blood stem cells to self-renew at least twelvefold in laboratory conditions.Multiplying blood stem cells in conditions outside the human body could greatly improve treatment options for blood cancers like leukemia and for many inherited blood diseases.Dr. Hanna Mikkola, a member of the  Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and senior author of the study, h...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Conditions:   Hematologic Diseases;   Chronic Myeloid Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Myelodysplastic Syndromes;   Non Hodgkin Lymphoma;   Stem Cell Transplant Complications;   Chronic Lymphocytic Leukemia Intervention:   Other: No intervention Sponsor:   Rigshospitalet, Denmark Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 9 November 2019Source: IDCasesAuthor(s): Lin Wei-Chen, Chang Ching, Ko Meng-Cheng, Lin Shu-MinAbstractAcute varicella zoster virus (VZV) infection is a common condition in children, which is considered a mild, self-limited disease with diffuse skin vesicular rash. However, disseminated VZV infection with multiple organ involvement can occur in immunocompromised patients with impaired T cell immunity including solid or hematopoietic stem cell transplant recipients, receiving immunosuppressive therapy, leukemia, lymphoma, and HIV infection. Prompt antiviral therapy is mandatory in those imm...
Source: IDCases - Category: Infectious Diseases Source Type: research
Publication date: Available online 7 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kaoru Morita, Masahiro Ashizawa, Yumiko Toda, Takashi Ikeda, Shin-ichiro Kawaguchi, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Chihiro Yamamoto, Kaoru Hatano, Shin-ichiro Fujiwara, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo MuroiAbstractAbout 40% of patients with diffuse large B cell lymphoma (DLBCL) relapse after or are refractory to standard chemotherapy with rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The evolution of Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) as a treatment modality has witnessed the cure of several haematological conditions such as leukaemia, lymphoma, multiple myeloma, myelodysplastic syndromes, thalassaemia and aplastic anaemia [1]. The many advances made in this domain, and the availability of excellent post transplant care have ensured increased longevity in recipients of allo-HSCT. It has been demonstrated in previous studies that patients who are disease-free at five years after HSCT have a 10-year survival rate that exceeds 80% [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
The evolution of allogeneic hematopoietic stem cell transplant (allo-HSCT) as a treatment modality has witnessed the cure of several hematologic conditions such as leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, thalassemia, and aplastic anemia [1]. The many advances made in this domain and the availability of excellent post-transplant care have ensured increased longevity in recipients of allo-HSCT. It has been demonstrated in previous studies that patients who are disease free at 5 years after HSCT have a 10-year survival rate that exceeds 80% [2].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Publication date: Available online 9 October 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Zohair Siddiqui, Juan Maldonado, Jeremy Grojean, Fei Ye, David Zhang, Janina Longtine, Tae-Hyuk Ahn, Huazhang GuoA quantitative chimerism test monitors engraftment of donor hematopoietic stem cells or relapse of leukemias or lymphomas in hematopoietic stem cell transplantation patients. The most common method used for chimerism testing is PCR amplification of short tandem repeat loci, followed by capillary gel electrophoresis. Manual data analysis is tedious and time consuming, as it involves the selection of informative...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
A treatment strategy of salvage chemotherapy and autologous stem-cell transplantation (ASCT) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients receiving hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a patient with refractory DLBCL with end-stage renal disease and successfully administered adjusted dosing of salvage chemotherapies and a conditioning regimen in ASCT without any adverse events.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
A treatment strategy of salvage chemotherapy and autologous stem cell transplantation in relapsed or refractory DLBCL patients on hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a refractory DLBCL patient with end-stage renal disease, and successfully administered adjusted dosing of salvage chemotherapies and conditioning regimen in autologous stem cell transplantation without any adverse events.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Denmark Health | Hematology | Leukemia | Lymphoma | Research | Stem Cell Therapy | Stem Cells | Transplants